Genenta Science S.p.A. (NASDAQ:GNTA) Sees Significant Growth in Short Interest

Genenta Science S.p.A. (NASDAQ:GNTA) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 11,600 shares, a growth of 152.2% from the September 30th total of 4,600 shares. Based on an average trading volume of 12,300 shares, the days-to-cover ratio is presently 0.9 days.

Institutional Investors Weigh In On Genenta Science

A hedge fund recently bought a new stake in Genenta Science stock. AlTi Global Inc. acquired a new stake in shares of Genenta Science S.p.A. (NASDAQ:GNTA) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned about 1.10% of Genenta Science as of its most recent filing with the SEC. 15.13% of the stock is owned by institutional investors and hedge funds.

Genenta Science Stock Performance

Genenta Science stock traded down $0.13 on Friday, hitting $5.22. 8,137 shares of the stock traded hands, compared to its average volume of 29,437. The business’s fifty day simple moving average is $4.49 and its 200 day simple moving average is $3.87. Genenta Science has a 1 year low of $2.20 and a 1 year high of $7.28.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Genenta Science in a report on Wednesday, October 2nd.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.